Back to Agenda
Update From the US FDA on Progress and Topics of Current Interest in US Biosimilar Policy, Regulation, and Outreach/Education
Session Chair(s)
Sarah Yim, MD
Director, Office of Therapeutic Biologics and Biosimilars, OND, CDER, FDA, United States
This session will include an update from members of the US FDA on progress and topics of current interest in US biosimilar policy, regulation, and outreach/education.
Learning Objective : Discuss topics of current interest in US biosimilar policy.
Speaker(s)
FDA Update
Head of Strategic Affairs, Verily, United States
FDA Update
Associate Director, Stakeholder Engagement and Education, OTBB, CDER, US FDA, United States
FDA Update
Division Director, Pharmaceutical Manufacturing Assessment VI, OPMA, CDER, US FDA, United States
Have an account?